Literature DB >> 557952

Synthesis of vaccinia viral antigens in HeLa cells in the presence of isatin beta-thiosemicarbazone.

E Katz, H Felix.   

Abstract

Vaccinia virus antigens, in HeLa cells treated with the antipox virus drug isatin beta-thiosemicarbazone (IBT), were analyzed by immunoprecipitation, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The total radioactivity in the immunoprecipitate was decreased to almost 50% in the presence of the drug as compared to its absence. An inhibition also occurred with an IBT-dependent mutant (IBT(D)) when growing in the absence of IBT. However, similar levels of radioactivity were observed in the immunoprecipitates from an IBT-resistant mutant (IBT(R)) grown in either the absence or presence of the drug. When the antigens within the immunoprecipitates were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, it was shown that the inhibition observed in the wild-type-infected cells in the presence of IBT and in the IBT(D)-infected cells in the absence of the drug, was quantitative, affecting the amounts of the different polypeptides more or less equally.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 557952      PMCID: PMC351953          DOI: 10.1128/AAC.11.2.202

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  ISOLATION AND PROPERTIES OF VACCINIA MUTANTS DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY.

Authors:  D R DUBBS; S KIT
Journal:  Virology       Date:  1964-02       Impact factor: 3.616

2.  The purification fo four strains of poxvirus.

Authors:  W K JOKLIK
Journal:  Virology       Date:  1962-09       Impact factor: 3.616

3.  The formation of vaccinia virus protein in the presence of 5-fluorodeoxyuridine.

Authors:  A J SHATKIN
Journal:  Virology       Date:  1963-06       Impact factor: 3.616

4.  Interference with the maturation of vaccinia virus by isatin beta-thiosemicarbazone.

Authors:  K B EASTERBROOK
Journal:  Virology       Date:  1962-06       Impact factor: 3.616

5.  Herpes simplex virus-specific polypeptides studied by polyacrylamide gel electrophoresis of immune precipitates.

Authors:  R W Honess; D H Watson
Journal:  J Gen Virol       Date:  1974-02       Impact factor: 3.891

6.  Identification of a large polypeptide precursor of avian oncornavirus proteins.

Authors:  V M Vogt; R Eisenman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-06       Impact factor: 11.205

7.  Immunological studies on viral polypeptide synthesis in cells replicating murine sarcoma-leukemia virus.

Authors:  G Shanmugam; G Vecchio; D Attardi; M Green
Journal:  J Virol       Date:  1972-09       Impact factor: 5.103

8.  Sequential protein synthesis following vaccinia virus infection.

Authors:  B Moss; N P Salzman
Journal:  J Virol       Date:  1968-10       Impact factor: 5.103

9.  Concerning the mechanism of action of interferon.

Authors:  W K Joklik; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1966-08       Impact factor: 11.205

10.  The effect of isatin beta thiosemicarbazone (IBT)-related compounds on IBT-resistant and on IBT-dependent mutants of vaccinia virus.

Authors:  E Katz; E Margalith; B Winer
Journal:  J Gen Virol       Date:  1974-11       Impact factor: 3.891

View more
  3 in total

1.  Selective repression of v-abl-encoded protein by N-methylisatin-beta-4',4'-diethylthiosemicarbazone and N-allylisatin-beta-4',4'-diallylthiosemicarbazone.

Authors:  Y Teitz; E Ladizensky; N Barko; E Burstein
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

2.  N-methylisatin-beta-4',4'-diethylthiosemicarbazone, an inhibitor of Moloney leukemia virus protein production: characterization and in vitro translation of viral mRNA.

Authors:  D Ronen; L Sherman; S Bar-Nun; Y Teitz
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

Review 3.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.